BioCentury | Dec 1, 2020

Viracta to start pivotal trial as public company following Sunesis merger, private placement

An investor syndicate is backing Viracta with $105 million in fresh capital as the biotech goes public via a reverse merger and plans a pivotal trial of its lead therapy targeting EBV-positive lymphomas. By merging...
BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

...from systemic lupus erythematosus patients, tissue with high T cell infiltration had higher protein levels pyruvate dehydrogenase kinase 2 (PDK2)...
BioCentury | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
BioCentury | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); pyruvate dehydrogenase kinase 1 (PDK1); serum/glucocorticoid regulated kinase 1 (SGK1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting PDK1 or SGK1 could help treat PI3Kα inhibitor-resistant breast cancer. In breast cancer patients, high tumor expression of SGK1 correlated with resistance...
BioCentury | Feb 11, 2016
Translation in Brief

Sugar rush

Partikula LLC is developing a series of compounds that elevate glucose and deplete lactate in the tumor microenvironment by modulating metabolism in tumors. Preclinical data for the lead compound - the tumor-targeted pyruvate dehydrogenase kinase (PDK)...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Pyruvate dehydrogenase kinase 2 (PDK2); PDK4

...Neurology INDICATION: Pain Mouse studies suggest dual PDK2 / PDK4 inhibitors could help treat inflammatory pain...
...treat inflammatory pain. In mice, intraplantar administration of an inflammatory adjuvant increased hindpaw expression of PDK2...
...include investigating the role of PDK2, PDK4 and other PDKs in additional pain models. TARGET/MARKER/PATHWAY: Pyruvate dehydrogenase kinase 2 (PDK2)...
BioCentury | May 22, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

...Publication and contact information Cardiovascular disease Restenosis Pyruvate dehydrogenase kinase 2 (PDK2) Rodent, rabbit and porcine studies suggest inhibiting PDK2...
...restenosis. In rodent and rabbit models of injury-induced arterial restenosis, shRNA against PDK2 or the PDK2...
Items per page:
1 - 10 of 24